Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants
A Phase I, Single-Centre, Open-Label, Repeat Dose Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of Elafibranor in Healthy Japanese and Non-Asian Participants.
Sponsor: Ipsen
Listed as NCT05543369, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Ipsen, it has been updated 10 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Jul 2023 — Aug 2023 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jun 2023 — Jul 2023 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .